Sacubitril/valsartan in the treatment of heart failure with severe left ventricular systolic dysfunction
2021
Abstract
The case study reveals a beneficial experience with sacubitril/valsartan instead of perindopril in the treatment of heart failure with left ventricular systolic dysfunction. An improvement of left ventricular ejection fraction from 14% to 60%, cardiac cachexia, and treatment compliance together with an increase from NYHA III functional class to NYHA I-II was achieved in the patient.
Other beneficial effects of the treatment are discussed, such as influencing renal function and compensation of diabetes mellitus.